About the Company
NeurAxis, Inc
BUSINESS DESCRIPTION
NeurAxis is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. NeurAxis is dedicated to advancing the science with its’ proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. We believe that superior science, evidence-based research, and building on its unparalleled body of clinical evidence is necessary for adoption by the medical...
NeurAxis, Inc News
-
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth...
11/17/2025 05:17 PMNeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results....
-
NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Cover...
11/12/2025 01:00 PMCARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commerc...
-
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Gro...
11/11/2025 12:00 PMConference call will be held today, Tuesday, November 11 at 9:00 am ETCARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “...
-
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday,...
11/04/2025 01:30 PMFinancial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ne...
-
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functiona...
10/24/2025 12:00 PMAchieves significant expansion of NeurAxis’ total addressable marketClearance now includes patients aged “8 years and older”Expanded age indication will u...
-
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on ...
09/18/2025 12:00 PMCARMEL, Ind., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company comme...
-
The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and Neu...
09/17/2025 09:53 AMZacks highlights Alphabet, IBM, Merck, SandRidge Energy, and NeurAxis, providing research insights on their growth prospects, market performance, and key risks ...
-
Top Research Reports for Alphabet, IBM & Merck...
09/16/2025 08:42 PMAlphabet, IBM, and Merck headline Zacks' latest research reports, with insights spanning AI, cloud growth, and pipeline challenges....
-
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth...
08/18/2025 06:27 PMNRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern....
Disclaimer: